These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 31402538

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network.
    Lancet; 2015 Mar 14; 385(9972):956-65. PubMed ID: 25468160
    [Abstract] [Full Text] [Related]

  • 23. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L, Pruzanski M, Shapiro D.
    Drug Discov Today; 2012 Sep 14; 17(17-18):988-97. PubMed ID: 22652341
    [Abstract] [Full Text] [Related]

  • 24. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K, Frisch K, Sørensen M, Munk OL, Hofmann AF, Horsager J, Schacht AC, Erickson M, Shapiro D, Keiding S.
    J Hepatol; 2021 Jan 14; 74(1):58-65. PubMed ID: 32717289
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E, Cholongitas E, Tziomalos K.
    World J Gastroenterol; 2016 Nov 07; 22(41):9039-9043. PubMed ID: 27895393
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
    Marchianò S, Biagioli M, Bordoni M, Morretta E, Di Giorgio C, Vellecco V, Roselli R, Bellini R, Massa C, Cari L, Urbani G, Ricci P, Monti MC, Giordano A, Brancaleone V, Bucci M, Zampella A, Distrutti E, Cieri E, Cirino G, Fiorucci S.
    J Am Heart Assoc; 2023 Dec 05; 12(23):e031241. PubMed ID: 37996988
    [Abstract] [Full Text] [Related]

  • 29. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    Al-Dury S, Wahlström A, Panzitt K, Thorell A, Ståhlman M, Trauner M, Fickert P, Bäckhed F, Fändriks L, Wagner M, Marschall HU.
    J Hepatol; 2019 Nov 05; 71(5):986-991. PubMed ID: 31254596
    [Abstract] [Full Text] [Related]

  • 30. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.
    Papazyan R, Liu X, Liu J, Dong B, Plummer EM, Lewis RD, Roth JD, Young MA.
    J Lipid Res; 2018 Jun 05; 59(6):982-993. PubMed ID: 29559521
    [Abstract] [Full Text] [Related]

  • 31. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E.
    Expert Opin Investig Drugs; 2020 Jun 05; 29(6):623-632. PubMed ID: 32552182
    [Abstract] [Full Text] [Related]

  • 32. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME, Sheikh MY, Trotter JF, Knapple W, Lawitz EJ, Abdelmalek MF, Newsome PN, Boursier J, Mathurin P, Dufour JF, Berrey MM, Shiff SJ, Sawhney S, Capozza T, Leyva R, Harrison SA, Younossi ZM.
    J Hepatol; 2023 Nov 05; 79(5):1110-1120. PubMed ID: 37517454
    [Abstract] [Full Text] [Related]

  • 33. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic Steatohepatitis Clinical Research Network.
    Hepatology; 2019 Aug 05; 70(2):522-531. PubMed ID: 30549292
    [Abstract] [Full Text] [Related]

  • 34. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S, Di Giorgio C, Distrutti E.
    Handb Exp Pharmacol; 2019 Aug 05; 256():283-295. PubMed ID: 31201552
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV, Tevethia HV, Arab JP, Candia R, Premkumar M, Kumar P, Sharma M, Reddy DN, Padaki NR.
    Clin Res Hepatol Gastroenterol; 2021 May 05; 45(3):101675. PubMed ID: 33722778
    [Abstract] [Full Text] [Related]

  • 36. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.
    Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M.
    World J Gastroenterol; 2018 Jan 14; 24(2):195-210. PubMed ID: 29375205
    [Abstract] [Full Text] [Related]

  • 37. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
    Rinella ME, Trotter JF, Abdelmalek MF, Paredes AH, Connelly MA, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Harrison SA.
    J Hepatol; 2019 Apr 14; 70(4):735-744. PubMed ID: 30529590
    [Abstract] [Full Text] [Related]

  • 38. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V, Karabouta Z, Polyzos SA.
    Eur J Pharmacol; 2019 Nov 15; 863():172661. PubMed ID: 31536725
    [Abstract] [Full Text] [Related]

  • 39. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, Bursulaya B, Hernandez ED, Wu J, Prashad M, Schlama T, Liu Y, Chu A, Schmeits J, Huang DJ, Hill R, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Liu B, Richmond W, Sancho-Martinez I, Phimister A, Seidel HM, Badman MK, Joseph SB, Laffitte B, Molteni V.
    J Med Chem; 2020 Apr 23; 63(8):3868-3880. PubMed ID: 31940200
    [Abstract] [Full Text] [Related]

  • 40. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J, Liu C, Zhou Z, Dou B, Huang J, Huang L, Zheng P, Fan S, Huang C.
    Phytother Res; 2021 Jun 23; 35(6):3351-3364. PubMed ID: 33784797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.